Educational Updates and Workshops:
Prof. Geoff Hackett In association with Bayer
Testosterone deficiency Syndrome (TDS) is common in men with Type 2 diabetes and in men with established cardiovascular disease, particularly heart failure. Several studies have consistently shown that low testosterone is associated with increased cardiovascular and all-cause mortality. The academic debate surrounding whether TDS is a risk factor, a marker of increased risk, or simply an association with chronic illness has resulted in few patients being diagnosed, even in high risk conditions. Well conducted RCTs have shown that TRT consistently improves sexual function and quality of life, reduces body fat, increases lean muscle mass, improves HbA1c, insulin resistance, lowers cholesterol and triglycerides. There is a strong and consistent body of evidence that Testosterone Replacement Therapy (TRT) for appropriately diagnosed hypogonadal men is well tolerated, efficacious and probably associated with reduction in cardiovascular risk and all-cause mortality. Crucially studies assessing mortality based on appropriate diagnosis achieving target therapeutic levels consistently show reduced mortality whereas 2 high profile studies showing increased mortality were flawed by lack of definite diagnosis and no evidence of adequate therapy. Dr Hackett will present the evidence from clinical studies and suggest a practical way forward to identify patients likely to benefit from TRT.